Neo100: Rare Pediatric Disease Designation for High-Grade Gliomas
NeOnc Technologies Holdings, Inc. has received Rare Pediatric Disease Designation (RPDD) from the FDA for its perillyl alcohol (NEO100™)...
CorVista Unveils Non-Invasive PCWP Test
CorVista Health presented preliminary data at the American College of Cardiology’s Annual Scientific Session (ACC.25) demonstrating the potential of...
Treace Medical Lapiplasty and Adductoplasty Show Positive Clinical Outcomes
Treace Medical Concepts announced positive interim data from three clinical studies of its bunion and midfoot correction surgical procedures...
Tremfya Approved for Crohn’s Disease, Challenging Skyrizi’s Growth
Tremfya (guselkumab), Johnson & Johnson’s IL-23 inhibitor, has received FDA approval for Crohn’s diseaseCrohn’s disease, adding to the existing...
Silexion Therapeutics Unveils Innovative Development Plan for SIL204
Silexion Therapeutics Corp. (NASDAQ: SLXN) is expanding the development plan for its next-generation siRNA candidate, SIL204, to treat KRAS-driven...
Corbus Doses First Patient in Phase 1 Obesity Study of CRB-913
Corbus Pharmaceuticals has dosed the first subject in a Phase 1 trial for CRB-913, an investigational drug for obesity....
Fibrogen FG-3246 Phase 1 Study Results in Metastatic Prostate Cancer
FibroGen announced positive results from a Phase 1 study of FG-3246, an antibody-drug conjugate targeting CD46, in patients with...
Anthos Therapeutics Shares New Data from Landmark AZALEA-TIMI 71 Study
Anthos Therapeutics presented new analyses from the AZALEA-TIMI 71 study at the American College of Cardiology Annual Scientific Session....
Bentracimab Reverses Ticagrelor Effects in Phase 3 Trial
SFJ Pharmaceuticals and SERB Pharmaceuticals announced positive final results from the Phase 3 REVERSE-IT trial of bentracimab, a ticagrelor...
Ninerafaxstat Improves Cardiometabolic HFpEF in Phase 2 Trial
Imbria Pharmaceuticals announced positive Phase 2 trial results for ninerafaxstat in patients with cardiometabolic heart failure with preserved ejection...